A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling

This study examined the pathological complete response (pCR) rate and safety of sequential gemcitabine-based combinations in breast cancer. We also examined gene expression profiles from tumour biopsies to identify biomarkers predictive of response. Indian women with large or locally advanced breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Julka, P K, Chacko, R T, Nag, S, Parshad, R, Nair, A, Oh, D S, Hu, Z, Koppiker, C B, Nair, S, Dawar, R, Dhindsa, N, Miller, I D, Ma, D, Lin, B, Awasthy, B, Perou, C M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361717/
https://www.ncbi.nlm.nih.gov/pubmed/18382427
http://dx.doi.org/10.1038/sj.bjc.6604322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361717/
https://www.ncbi.nlm.nih.gov/pubmed/18382427
http://dx.doi.org/10.1038/sj.bjc.6604322

Ejemplares similares